No clinically significant infections as judged by the treating investigator N or N disease detected clinically or by imaging Uncontrolled clinically significant arrhythmias. Has a medical history of clinically significant lung disease Clinically significant anemia due to non-MDS etiologies Treatment with clinically significant metabolic CYPA inducers within days before the first dose of study drug; clinically significant CYPA inducers are not permitted during the study Participant has clinically significant uncontrolled conditions. Current diagnosis of any other active or clinically significant nonbreast cancer Evidence of increased intracranial pressure (clinically significant papilledema, vomiting, and nausea, or reduced level of consciousness) Clinically significant neurologic event (stroke) or any neurological deficit lasting > hours; Have any clinically significant disease considered by the investigator to interfere with study participation Has clinically significant heart disease that affects normal activities. Clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or central nervous system disorders. Current, clinically significant, active infection that in the opinion of the Investigator would make them an unfit participant in the trial Women who have had an abnormal gynecology exam within the last three years with clinically significant findings, such as secondary dysmenorrhea, polyps, or atypia, which in the opinion of the Investigator would interfere with the study. Clinically significant active infection, in the judgment of the investigator Patients with acute or chronic hepatic dysfunction as evidenced by clinically significant abnormalities in albumin, total protein, or prothrombin time, or evidence of hepatic injury with clinically important (> grade ) changes in AST, ALT, ALP, bilirubin, or GGT values. Clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or neurological conditions. Evidence of increased intracranial pressure (clinically significant papilledema, vomiting and nausea or reduced level of consciousness) Clinically significant, uncontrolled heart disease No clinically significant infections as judged by the treating investigator TREATMENT WITH SJCAR: Electrocardiogram (EKG) without evidence of clinically significant arrhythmia Evidence of increased intracranial pressure (midline shift > mm, clinically significant papilledema, vomiting and nausea, or reduced level of consciousness) Evidence of increased intracranial pressure (midline shift > mm, clinically significant papilledema) Ongoing clinically significant infection at or near the incident lesion Participants with a history of clinically significant, uncontrolled heart disease and/or repolarization abnormalities Concurrent clinically significant infections as determined by the treating Investigator. Has clinically significant lung disease or is suspected to have such diseases by imaging at Screening Treatment with clinically significant metabolic inducers within days before the first dose of study drug; clinically significant metabolic inducers are not permitted during the study Clinically significant abnormal laboratory results Current, serious, clinically significant cardiac arrhythmias as determined by the investigator, or patient receiving a digitalis derivative. Treatment with clinically significant metabolic enzyme inducers within days before the first dose of the study drug; clinically significant metabolic enzyme inducers are not permitted during this study No clinically significant infections as judged by the treating investigator Any clinically significant uncontrolled concomitant disease Has any other clinically significant abnormal laboratory value in the opinion of the investigator Acute or chronic, clinically significant hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical examination, electrocardiography (EKG), and/or laboratory screening test clinically significant active infection clinically significant CNS disorder Acute or chronic, clinically significant hematologic, pulmonary, cardiovascular, hepatic renal, and/or other functional abnormality that would jeopardize the health and safety of the participant as determined by the investigator based on medical history, physical examination, laboratory values, and/or diagnostic studies Clinically significant dry eye or contact lens use Patients with any clinically significant autoimmune disease uncontrolled with treatment Active or clinically significant Gastric Antral Vascular Ectasia (GAVE, \watermelon stomach\) Treatment with clinically significant metabolic enzyme inducers within days before the first dose of the study drug; clinically significant metabolic enzyme inducers are not permitted during this study (CYPA/ inducers) No clinically significant infections or any other medical condition(s) that render the subject ineligible for high dose IL- therapy as judged by the treating investigator History of clinically significant auditory or ocular toxicity with ICT Patients with clinically significant cardiomyopathy requiring treatment No clinically significant uncontrolled infections as determined by investigator No clinically significant infections as judged by the treating investigator Another cancer that is not clinically stable Complete metabolic profile (CMP) - no clinically significant findings Clinically significant increased intracranial pressure (e.g., impending herniation), uncontrolled seizures, or requirement for immediate palliative treatment Clinically significant, uncontrolled heart diseases. Subject has a clinically significant uncontrolled condition(s) s described in the protocol. Subject has a clinically significant peripheral artery disease, e.g., those with claudication, within months Has any clinically significant infection Acute or chronic, clinically significant hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical examination, electrocardiogram (EKG), and/or laboratory screening test Patients with clinically significant increased intracranial pressure (e.g., impending herniation), uncontrolled seizures, or requirement for immediate palliative treatment Acute or chronic, clinically significant hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical examination, electrocardiogram (EKG), and/or laboratory screening test Clinically significant uncontrolled illness Patients with any clinically significant autoimmune disease uncontrolled with treatment Clinically significant heart disease Clinically significant comorbid disease or other underlying condition, including major autoimmune disorders that would contraindicate study therapy or confuse interpretation of study results Clinically significant comorbid disease or other underlying condition, including major autoimmune disorders that would contraindicate study therapy or confuse interpretation of study results Evidence of clinically significant neuropathy (> Grade ) by physical exam. Any Grade or higher lab abnormalities should be discussed and approved by the Medical Monitor prior to enrollment (even if not considered clinically significant); Treatment with clinically significant metabolic enzyme inducers within days before the first dose of the study drug; clinically significant metabolic enzyme inducers are not permitted during this study Clinically significant, uncontrolled heart diseases Electrocardiogram (EKG) without clinically significant abnormality Clinically significant abnormality on ophthalmologic examination during screening evaluation Clinically significant, uncontrolled heart diseases. Evidence of clinically significant pancreatitis as determined by the investigator Any significant ophthalmologic abnormality No clinically significant infections as judged by the treating investigator Any significant diseases (other than HL) or clinically significant findings, including psychiatric and behavioral problems, medical history and/or physical examination findings that would preclude the subject from participating in the study Clinically significant systemic disease, as determined by the investigator, which could affect study participation or study results - Participant has clinically significant uncontrolled condition(s) as described in the protocol. Clinically significant surgery within weeks of enrollment. Active clinically significant infection Active clinically significant infection within -days of study treatment. History or evidence of current clinically significant uncontrolled arrhythmias Known, clinically significant carotid artery disease Any clinically significant electrolyte imbalance, particularly hypokalemia and hypomagnesemia, should be corrected before treatment Uncontrolled and clinically significant disease-related metabolic disorder Patients must not have clinically significant autoimmune disease that requires treatment with immunosuppressant medications Any clinically significant active infection that requires systemic treatment at the time of enrollment Clinically significant resting bradycardia Treatment for clinically-significant hyperglycemia, hyperlipidemia, or hypertension that develops on study is required Clinically significant uncontrolled condition(s). Clinically significant and unexplained elevated liver or renal function tests Patients with abnormal serum chemistry values, which in the opinion of the Investigator is considered to be clinically significant, will be excluded from the study Second primary malignancy that is clinically detectable or clinically significant at the time of consideration for study enrollment Any sign of clinically significant bleeding Clinically significant organ/system disease unrelated to RCC that in the judgment of the investigator should preclude treatment with dalantercept or axitinib. Evidence of active tuberculosis or recent (< week prior to first scheduled dosing) clinically significant infection requiring systemic therapy. Has a medical history of clinically significant lung disease Clinically significant heart disease Has all prior treatment (i.e., chemotherapy, immunotherapy, radiotherapy) related clinically significant toxicities resolve to ? Grade per NCI CTCAE, Version . or are clinically stable and not clinically significant, at time of consent significant fatigue Clinically quantifiable disease burden defined as at least one of the following: Patients who have received treatment with clinically significant enzyme inducers within days prior to registration are not eligible Has all prior treatment (i.e., chemotherapy, immunotherapy, radiotherapy) related clinically significant toxicities resolve to ? Grade per CTCAE, version . or are clinically stable and not clinically significant, at time of enrollment Have ongoing clinically significant adverse event(s) due to prior treatments administered as determined by the investigator. Clinically significant hypercalcemia (including vomiting, dehydration and neurological symptoms) Other clinically significant disease or co-morbidity that may adversely affect the safe delivery of treatment within this trial Clinically significant pulmonary disease Subject with clinically significant wound Serum bilirubin < x upper limit of normal, or considered not clinically significant by the study doctor or designee Known clinically significant hypotension Known clinically significant autoimmune disorders requiring on-going systemic immune-suppression for control Have altered immunity such as autoimmune disorders, clinically significant anemia, hemophilia, and blood dyscrasias Another malignancy that is clinically significant or requires active intervention (chemotherapy or radiation) No clinically significant infections as judged by the treating investigator. Uncontrolled clinically significant pulmonary disease. History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or drug intake Clinically significant uncontrolled condition(s) Clinically significant peripheral artery disease (e.g., claudication with < block) or any other arterial thrombotic event Have current or prior history of infection or clinically significant adverse events (AEs) associated with an exogenous implant(s) or device(s) that cannot be easily removed Clinically significant valvular heart disease Patients with clinically significant cardiomyopathy requiring treatment Concurrent disease or condition that would interfere with study participation or safety, such as:\r\n* Active, clinically significant infection requiring the use of parenteral anti-microbial agents, or grade > by NCI CTCAE (v .) within days prior to enrollment\r\n* Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders\r\n* Non-healing wound, ulcer, or bone fracture\r\n* Bone marrow disorder including myelodysplasia No arrhythmia interpreted by the study cardiologist to be clinically significant Significant comorbidity: Patients with clinically significant and uncontrolled major disease or disorder that could exacerbate potential toxicities, confound safety assessments, require excluded therapy for management, or limit study compliance. Clinically significant conditions that increase the risk for antiangiogenic therapy. Treatment with clinically significant metabolic enzyme inducers within days before the first dose of the study drug; clinically significant metabolic enzyme inducers are not permitted during this study Evidence of increased intracranial pressure (midline shift > mm, clinically significant papilledema, vomiting and nausea, or reduced level of consciousness) History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or oral drug intake Clinically significant acute pancreatitis within weeks of treatment with protocol therapy as indicated by the presence of two of the three following criteria: abdominal pain in the epigastrium, often with radiation to the back, serum amylase and/or lipase greater than three times the upper limit of normal, and/or characteristic findings (peripancreatic inflammation, fat necrosis, etc.) from abdominal imaging; clinically significant will be defined as that requiring oral narcotics or hospital admission Clinically significant resting bradycardia Patients with a history of clinically significant cutaneous drug reaction to minocycline, as documented in the patient medical records History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or oral drug intake No significant immunodeficiency History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or oral drug intake Clinically significant valvular heart disease Presence of clinically relevant ascitis Subject has a clinically significant peripheral artery disease, e.g., those with claudication, within months Clinically significant illness that requires medical treatment within weeks or a clinically significant infection that requires medical treatment within weeks of dosing Clinically significant cardiovascular disease defined as: i. Left ventricular ejection fraction (LVEF) ? %, measured within months prior to Day confirmed by ECHO/MUGA ii. Congestive heart failure requiring medical therapy iii. Chronic stable angina requiring medical therapy iv. Prior cerebrovascular accident with sequelae c. Clinically significant pulmonary disease defined as: i. Forced expiratory volume in second (FEV) ? % of expected ii. Lung diffusing capacity for carbon monoxide (DLCO) ? % of expected Confirmed by pulmonary tests. d. Diabetes mellitus with symptomatic end-organ damage (e.g., retinopathy, nephropathy, neuropathy, vasculopathy) e. Autoimmune inflammatory conditions (e.g., rheumatoid arthritis, systemic lupus erythematous, inflammatory bowel disease, or similar) requiring chronic disease modifying therapy (e.g., etanercept, adalimumab, infliximab, rituximab, methotrexate, or similar) f. Class III obesity defined as a Body Mass Index (BMI) > kg/m g. Renal impairment defined as serum creatinine > . mg/dL (> mol/L) or creatinine clearance < ml/min h. Clinically significant cognitive impairment defined as requiring medical therapy and/or assistance with activities of daily living History or clinical evidence of any surgical or medical condition which the investigator judges as likely to interfere with the results of the study or pose an additional risk in participating (eg, active or clinically significant history of disease involving a major organ systemvascular, cardiac, pulmonary, hepatic, gastrointestinal, gynecologic, hematologic, neurologic, neoplastic, renal, endocrine or immunodeficiency, autoimmune or clinically significant active psychiatric disorders) Patients with clinically significant co-morbid conditions, including, but not limited to: hypotension, chronic interstitial lung disease, uncontrolled diabetes Clinically quantifiable disease burden defined as: Uncontrolled clinically significant arrhythmias Has clinically significant heart disease that affects normal activities History of clinically significant heart problems Clinically significant electrolyte imbalance ? Grade . Evidence of increased intracranial pressure (midline shift > mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness) Ongoing or clinically significant active infection as judged by the investigator. Ongoing or clinically significant active infection as judged by the investigator. Patients with clinically significant severe cardiorespiratory disease. Patients with clinically significant ophthalmologic findings (as determined by an ophthalmologist) during screening should be excluded from the trial Clinically significant electrolyte imbalance ? grade . Active and clinically significant systemic or localized infection. Any sign of clinically significant bleeding History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or oral drug intake Clinically significant bleeding within days before enrollment Clinically significant bleeding within days of study Day Clinically significant hypotension Clinically significant autoimmune disorders requiring on-going systemic immune-suppression for control Clinically significant central nervous system disease defined as untreated, progressive, or requiring steroids for control of symptoms. A history or evidence of current clinically significant uncontrolled arrhythmias; Clinically significant active pulmonary risk History of repeated and clinically relevant episodes of syncope or other paroxysmal, ventricular, or other significant arrhythmias Subject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to:\r\n* Active systemic fungal infection\r\n* Diagnosis of fever and neutropenia within week prior to study drug administration Clinically significant resting bradycardia Any other clinically significant heart disease Clinically significant anemia unrelated to MDS No evidence of a clinically significant active infection Clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or central nervous system disorders Clinically significant abnormalities of glucose metabolism. Clinically-significant thrombosis within months of screening Second primary malignancy that is clinically detectable or clinically significant at the time of consideration for study enrollment Lifetime history of suicidality, homicidality, or clinically significant hostility/aggression Clinically significant resting bradycardia Other clinically significant heart disease Persistent clinically significant toxicities from prior chemo ? Grd Persistent clinically significant toxicities from prior chemo ? Grd History of any clinically significant local or systemic infectious disease within weeks prior to initial treatment administration No clinically significant infections as judged by the treating investigator. Clinically significant obstructive airway disease Subjects must be free of any clinically significant disease other than cancer that would interfere with the study evaluations Any clinically significant electrolyte imbalance, particularly hypokalemia and hypomagnesemia, should be corrected before treatment Subjects must be free of any clinically significant disease other than cancer that would interfere with the study evaluations Serum bilirubin < x ULN, or considered not clinically significant by the study doctor or designee Patient has clinically active diverticular disease Patients with clinically significant illnesses which, according to the Investigator, could compromise participation in the study; Uncontrolled clinically significant arrhythmia in last months. Married or cohabiting with a significant other of either gender for more than one year Manometry felt to be clinically indicated Report a clinically significant level of FCR (as assessed with the Fear of Cancer Recurrence Inventory Short Form >= ) Concurrent clinically significant infections as determined by the treating investigator. Clinically significant uncontrolled condition(s). Clinically significant gastrointestinal disorder Symptomatic tachycardia and uncontrolled hypertension (determined to be clinically significant by the PI) Symptomatic tachycardia and uncontrolled hypertension (determined to be clinically significant by the PI) History of or current clinically significant immunodeficiency History of or current clinically significant alloimmunization to leukocyte antigens Patient has acute bleeding that is clinically significant within hours before the start of study treatment. Clinically significant bacteremia or fungemia Presence of clinically significant infections or congenital or acquired immunodeficiency Subjects with clinically significant increased intracranial pressure (eg, impending herniation or requirement for immediate palliative treatment) or uncontrolled seizures Clinically significant edema requiring diuretic therapy Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. Be clinically stable Liver enzymes without clinically significant abnormalities after review by the study physicians Active clinically significant infection Significant ophthalmologic abnormality, Uncontrolled, clinically significant pulmonary disease. no evidence of active/clinically significant bleeding. May be evidence of punctate hemorrhage w/in tumor as long as not considered clinically significant to warrant urgent surgical evacuation Clinically significant resting bradycardia Concomitant use or administration of clinically significant enzyme inducers less than or equal to (<=) days before the first dose of TAK-. Clinically significant active infection is clinically unstable and/or